GGrantIndex
← Leaderboards

Peter D. Cole

Albert Einstein College Of Medicine

$5,736,884
Attributed
$11,287,375
Total exposure
5
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.6M · FY201425
$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,287,375 · 5

By mechanism

R01$10,875,315 · 4
R21$412,060 · 1

Top collaborators

Most similar at Albert Einstein College Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Impaired Cognition

Research focus

Impaired CognitionCancer TherapyCognitive DeficitsCognitive FunctionQuality Of LifeNeurotoxicityClinical TrialsPreventBrainChildSchoolsFunctional DisorderSurvivorsMemoryImpairmentChemotherapyAcute Lymphocytic LeukemiaBiological MarkersCurative TreatmentsAttentionMalignant Childhood NeoplasmChildhood Acute Lymphocytic LeukemiaFoundationsChildhood Leukemia

Grant awards (20)

Identification of novel biomarkers and therapeutic strategies in chemobrain.$593,672
R01 · FY2025 · CA
Characterization of brain dysfunction during development in survivors of childhood acute lymphoblastic leukemia$844,664
R01 · FY2024 · CA
Identification of novel biomarkers and therapeutic strategies in chemobrain.$593,617
R01 · FY2024 · CA
Characterization of brain dysfunction during development in survivors of childhood acute lymphoblastic leukemia$925,510
R01 · FY2023 · CA
Characterization of brain dysfunction during development in survivors of childhood acute lymphoblastic leukemia$937,915
R01 · FY2022 · CA
Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL$666,287
R01 · FY2022 · CA · contact PI
Characterization of brain dysfunction during development in survivors of childhood acute lymphoblastic leukemia$949,119
R01 · FY2021 · CA
Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL$682,392
R01 · FY2021 · CA · contact PI
Characterization of brain dysfunction during development in survivors of childhood acute lymphoblastic leukemia$931,687
R01 · FY2020 · CA
Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL$679,885
R01 · FY2020 · CA · contact PI
Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL$659,113
R01 · FY2019 · CA · contact PI
Identifying children with subclinical neurocognitive decline and susceptibility to oxidative damage during the early months of therapy for ALL$695,429
R01 · FY2018 · CA · contact PI
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats$329,925
R01 · FY2018 · CA · contact PI
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats$346,525
R01 · FY2017 · CA · contact PI
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats$346,525
R01 · FY2016 · CA · contact PI
Markers of Cognitive Decline During Treatment for Childhood ALL$215,938
R21 · FY2016 · CA · contact PI
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats$262,856
R01 · FY2015 · CA · contact PI
Markers of Cognitive Decline During Treatment for Childhood ALL$196,122
R21 · FY2015 · CA · contact PI
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats$83,669
R01 · FY2015 · CA · contact PI
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats$346,525
R01 · FY2014 · CA · contact PI